Published in Neuroscience on August 27, 2008
Early autophagic response in a novel knock-in model of Huntington disease. Hum Mol Genet (2010) 1.99
Huntington's disease: can mice lead the way to treatment? Neuron (2011) 1.71
Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease. Neuropsychopharmacology (2011) 1.66
Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. Neuroscience (2011) 1.62
Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175. PLoS One (2012) 1.53
Choosing an animal model for the study of Huntington's disease. Nat Rev Neurosci (2013) 1.47
The use of a running wheel to measure activity in rodents: relationship to energy balance, general activity, and reward. Neurosci Biobehav Rev (2012) 1.45
Quantification of gait parameters in freely walking rodents. BMC Biol (2015) 1.44
Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity. J Biol Chem (2009) 1.34
Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease. PLoS One (2012) 1.31
Automated quantitative gait analysis in animal models of movement disorders. BMC Neurosci (2010) 1.31
Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease. J Neurosci (2009) 1.28
Elevated NADPH oxidase activity contributes to oxidative stress and cell death in Huntington's disease. Hum Mol Genet (2012) 1.25
Mutant huntingtin-impaired degradation of beta-catenin causes neurotoxicity in Huntington's disease. EMBO J (2010) 1.19
Dysfunctions in circadian behavior and physiology in mouse models of Huntington's disease. Exp Neurol (2010) 1.18
Mouse models of Huntington's disease and methodological considerations for therapeutic trials. Biochim Biophys Acta (2009) 1.14
Alterations in striatal synaptic transmission are consistent across genetic mouse models of Huntington's disease. ASN Neuro (2010) 1.09
Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models. Hum Mol Genet (2009) 1.09
Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease. Hum Mol Genet (2013) 1.08
Dopamine and glutamate in Huntington's disease: A balancing act. CNS Neurosci Ther (2010) 1.03
Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms. ASN Neuro (2010) 1.03
A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease. J Neurophysiol (2011) 1.01
A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease. J Neurosci (2013) 1.00
Dysregulated Neuronal Activity Patterns Implicate Corticostriatal Circuit Dysfunction in Multiple Rodent Models of Huntington's Disease. Front Syst Neurosci (2011) 0.98
Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice. Neurobiol Dis (2010) 0.98
The Huntington's disease mutation impairs Huntingtin's role in the transport of NF-κB from the synapse to the nucleus. Hum Mol Genet (2010) 0.97
Preferential accumulation of N-terminal mutant huntingtin in the nuclei of striatal neurons is regulated by phosphorylation. Hum Mol Genet (2011) 0.96
Loss of corticostriatal and thalamostriatal synaptic terminals precedes striatal projection neuron pathology in heterozygous Q140 Huntington's disease mice. Neurobiol Dis (2013) 0.95
Disruption of Rab11 activity in a knock-in mouse model of Huntington's disease. Neurobiol Dis (2009) 0.95
Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats. Exp Neurol (2010) 0.93
Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease. Mol Neurodegener (2012) 0.93
Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models. J Neurosci (2012) 0.92
Proteomic analysis of wild-type and mutant huntingtin-associated proteins in mouse brains identifies unique interactions and involvement in protein synthesis. J Biol Chem (2012) 0.92
Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis. FEBS J (2013) 0.90
A broad phenotypic screen identifies novel phenotypes driven by a single mutant allele in Huntington's disease CAG knock-in mice. PLoS One (2013) 0.89
Wnts in adult brain: from synaptic plasticity to cognitive deficiencies. Front Cell Neurosci (2013) 0.88
Striatal atrophy and dendritic alterations in a knock-in mouse model of Huntington's disease. Brain Res Bull (2012) 0.86
Mood disorders in Huntington's disease: from behavior to cellular and molecular mechanisms. Front Behav Neurosci (2014) 0.86
The Q175 mouse model of Huntington's disease shows gene dosage- and age-related decline in circadian rhythms of activity and sleep. PLoS One (2013) 0.85
Induced Pluripotent Stem Cells in Huntington's Disease Research: Progress and Opportunity. J Huntingtons Dis (2016) 0.85
Dysregulation of dopamine receptor D2 as a sensitive measure for Huntington disease pathology in model mice. Proc Natl Acad Sci U S A (2012) 0.85
The Wnt receptor Ryk reduces neuronal and cell survival capacity by repressing FOXO activity during the early phases of mutant huntingtin pathogenicity. PLoS Biol (2014) 0.85
Htt CAG repeat expansion confers pleiotropic gains of mutant huntingtin function in chromatin regulation. Hum Mol Genet (2015) 0.84
Mouse models of polyglutamine diseases: review and data table. Part I. Mol Neurobiol (2012) 0.84
Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease. Mol Cell Neurosci (2011) 0.84
The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice. Neurobiol Dis (2012) 0.83
Altered excitatory and inhibitory inputs to striatal medium-sized spiny neurons and cortical pyramidal neurons in the Q175 mouse model of Huntington's disease. J Neurophysiol (2015) 0.83
The knockout of secretin in cerebellar Purkinje cells impairs mouse motor coordination and motor learning. Neuropsychopharmacology (2013) 0.83
Differential loss of thalamostriatal and corticostriatal input to striatal projection neuron types prior to overt motor symptoms in the Q140 knock-in mouse model of Huntington's disease. Front Syst Neurosci (2014) 0.81
Abnormal burst patterns of single neurons recorded in the substantia nigra reticulata of behaving 140 CAG Huntington's disease mice. Neurosci Lett (2012) 0.81
Reduced expression of conditioned fear in the R6/2 mouse model of Huntington's disease is related to abnormal activity in prelimbic cortex. Neurobiol Dis (2011) 0.81
Reversal learning and associative memory impairments in a BACHD rat model for Huntington disease. PLoS One (2013) 0.81
Rescuing the Corticostriatal Synaptic Disconnection in the R6/2 Mouse Model of Huntington's Disease: Exercise, Adenosine Receptors and Ampakines. PLoS Curr (2010) 0.80
Characterization of Striatal Neuronal Loss and Atrophy in the R6/2 Mouse Model of Huntington's Disease. PLoS Curr (2014) 0.80
Age-Dependent Resistance to Excitotoxicity in Htt CAG140 Mice and the Effect of Strain Background. J Huntingtons Dis (2012) 0.80
N-terminal Huntingtin Knock-In Mice: Implications of Removing the N-terminal Region of Huntingtin for Therapy. PLoS Genet (2016) 0.80
Striatal synaptosomes from Hdh140Q/140Q knock-in mice have altered protein levels, novel sites of methionine oxidation, and excess glutamate release after stimulation. J Huntingtons Dis (2013) 0.80
Use of a force-sensing automated open field apparatus in a longitudinal study of multiple behavioral deficits in CAG140 Huntington's disease model mice. Behav Brain Res (2015) 0.79
Differential degradation of motor deficits during gradual dopamine depletion with 6-hydroxydopamine in mice. Neuroscience (2015) 0.79
CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease. J Clin Invest (2017) 0.78
Ubiquitin-activating enzyme activity contributes to differential accumulation of mutant huntingtin in brain and peripheral tissues. J Neurosci (2014) 0.78
Cholinergic interneurons in the Q140 knockin mouse model of Huntington's disease: Reductions in dendritic branching and thalamostriatal input. J Comp Neurol (2016) 0.77
A Longitudinal Motor Characterisation of the HdhQ111 Mouse Model of Huntington's Disease. J Huntingtons Dis (2016) 0.77
Chromosome substitution strain assessment of a Huntington's disease modifier locus. Mamm Genome (2015) 0.76
A Drosophila model of Huntington disease-like 2 exhibits nuclear toxicity and distinct pathogenic mechanisms from Huntington disease. Hum Mol Genet (2016) 0.75
Corticostriatal Dysfunction in Huntington's Disease: The Basics. Front Hum Neurosci (2016) 0.75
PIAS1 Regulates Mutant Huntingtin Accumulation and Huntington's Disease-Associated Phenotypes In Vivo. Neuron (2016) 0.75
Sudden death due to paralysis and synaptic and behavioral deficits when Hip14/Zdhhc17 is deleted in adult mice. BMC Biol (2016) 0.75
Trendelenburg-Like Gait, Instability and Altered Step Patterns in a Mouse Model for Limb Girdle Muscular Dystrophy 2i. PLoS One (2016) 0.75
Mutant Huntingtin Impairs BDNF Release from Astrocytes by Disrupting Conversion of Rab3a-GTP into Rab3a-GDP. J Neurosci (2016) 0.75
Beneficial effects of glatiramer acetate in Huntington's disease mouse models: evidence for BDNF-elevating and immunomodulatory mechanisms. Brain Res (2017) 0.75
Mutant huntingtin inhibits αB-crystallin expression and impairs exosome secretion from astrocytes. J Neurosci (2017) 0.75
Differential HspBP1 expression accounts for the greater vulnerability of neurons than astrocytes to misfolded proteins. Proc Natl Acad Sci U S A (2017) 0.75
Depression: a new animal model sensitive to antidepressant treatments. Nature (1977) 8.76
The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) (1985) 7.53
Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry (2007) 5.49
The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev (2005) 4.64
Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet (2003) 4.07
Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum Mol Genet (2001) 3.84
The neuroanatomical and neurochemical basis of conditioned fear. Neurosci Biobehav Rev (1999) 3.66
Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci (2008) 3.54
Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol (2003) 3.08
Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology (2004) 2.81
Motor disorder in Huntington's disease begins as a dysfunction in error feedback control. Nature (2000) 2.81
Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol Psychiatry (2007) 2.71
In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Mol Psychiatry (2004) 2.55
Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet (2007) 2.54
Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures. Mov Disord (2006) 2.23
Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum Mol Genet (1999) 2.20
Neuropsychiatric aspects of Huntington's disease. J Neurol Neurosurg Psychiatry (2001) 2.04
The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Res Bull (2006) 2.00
Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis. Hum Mol Genet (2003) 1.96
Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. J Comp Neurol (2005) 1.95
Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology (2005) 1.95
Microglial activation in presymptomatic Huntington's disease gene carriers. Brain (2007) 1.93
Circadian modulation of learning and memory in fear-conditioned mice. Behav Brain Res (2002) 1.84
Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: application of a three-dimensional, stereologic counting method. J Comp Neurol (1998) 1.83
Estrogen increases locomotor activity in mice through estrogen receptor alpha: specificity for the type of activity. Endocrinology (2003) 1.73
Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. Hum Mol Genet (2002) 1.67
Transgenic rat model of Huntington's disease. Hum Mol Genet (2003) 1.66
Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc Natl Acad Sci U S A (2000) 1.66
Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia (2007) 1.54
Mouse defensive behaviors: pharmacological and behavioral assays for anxiety and panic. Neurosci Biobehav Rev (2001) 1.50
Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. J Neurosci (2002) 1.48
Quantitative neuropathological changes in presymptomatic Huntington's disease. Ann Neurol (2001) 1.44
The Mouse Defense Test Battery: pharmacological and behavioral assays for anxiety and panic. Eur J Pharmacol (2003) 1.44
Longitudinal cognitive and motor changes among presymptomatic Huntington disease gene carriers. Arch Neurol (1999) 1.41
Knock-in mouse models of Huntington's disease. NeuroRx (2005) 1.40
Motor timing variability increases in preclinical Huntington's disease patients as estimated onset of motor symptoms approaches. J Int Neuropsychol Soc (2007) 1.38
Longitudinal evaluation of the Hdh(CAG)150 knock-in murine model of Huntington's disease. J Neurosci (2007) 1.38
Preclinical Huntington's disease: compensatory brain responses during learning. Ann Neurol (2006) 1.36
fMRI detection of early neural dysfunction in preclinical Huntington's disease. J Int Neuropsychol Soc (2007) 1.35
Exercise enhances and protects brain function. Exerc Sport Sci Rev (2002) 1.35
Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing. Neurobiol Dis (2005) 1.33
Subtle changes among presymptomatic carriers of the Huntington's disease gene. J Neurol Neurosurg Psychiatry (2000) 1.32
Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiol Dis (2006) 1.25
Specific psychiatric manifestations among preclinical Huntington disease mutation carriers. Arch Neurol (2007) 1.25
Hypothalamic-endocrine aspects in Huntington's disease. Eur J Neurosci (2006) 1.25
Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington's disease. Hum Mol Genet (2006) 1.25
Comparison of incremental and accelerating protocols of the rotarod test for the assessment of motor deficits in the 6-OHDA model. J Neurosci Methods (2006) 1.20
Confirmation of subtle motor changes among presymptomatic carriers of the Huntington disease gene. Arch Neurol (2000) 1.19
Altered fear circuits in 5-HT(1A) receptor KO mice. Biol Psychiatry (2000) 1.17
Implicit and explicit aspects of sequence learning in pre-symptomatic Huntington's disease. Parkinsonism Relat Disord (2008) 1.16
Effect of ovarian steroids on footshock avoidance learning and retention in female mice. Physiol Behav (1995) 1.14
The neurobiology of dopamine signaling. Biosci Rep (2001) 1.14
The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease. J Neurochem (2002) 1.13
Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease. Exp Neurol (2000) 1.11
Sex differences in behavior and striatal ascorbate release in the 140 CAG knock-in mouse model of Huntington's disease. Behav Brain Res (2007) 1.09
Sex differences in a transgenic rat model of Huntington's disease: decreased 17beta-estradiol levels correlate with reduced numbers of DARPP32+ neurons in males. Hum Mol Genet (2008) 1.07
Evidence for dysfunction of the nigrostriatal pathway in the R6/1 line of transgenic Huntington's disease mice. Neurobiol Dis (2002) 1.06
Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse. Neuroscience (2003) 1.04
Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease. Philos Trans R Soc Lond B Biol Sci (1999) 1.03
N-Acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington's disease mice. Neuroreport (2000) 1.01
Influence of age on behavioural response in the light/dark paradigm. Physiol Behav (1999) 0.98
The use of transgenic and knock-in mice to study Huntington's disease. Cytogenet Genome Res (2003) 0.97
Fear recognition across the menstrual cycle. Horm Behav (2005) 0.95
Interactions between body temperature and wheel running over the estrous cycle in rats. Physiol Behav (1991) 0.93
The operant serial implicit learning task reveals early onset motor learning deficits in the Hdh knock-in mouse model of Huntington's disease. Eur J Neurosci (2007) 0.92
Exploratory activity and fear conditioning abnormalities develop early in R6/2 Huntington's disease transgenic mice. Behav Neurosci (2003) 0.90
Selective striatal neuron loss and alterations in behavior correlate with impaired striatal function in Huntington's disease transgenic rats. Neurobiol Dis (2006) 0.90
Striking changes in anxiety in Huntington's disease transgenic mice. Brain Res (1998) 0.90
Influence of estrus cycle and ageing on activity patterns in two inbred mouse strains. Behav Brain Res (2005) 0.88
Longitudinal personality changes among presymptomatic Huntington disease gene carriers. Neuropsychiatry Neuropsychol Behav Neurol (2002) 0.87
Mild prenatal stress in rats is associated with enhanced conditioned fear. Physiol Behav (2003) 0.86
Behaviour changes in a transgenic model of Huntington's disease. Behav Brain Res (2006) 0.86
Quantitative study of gliosis in schizophrenia and Huntington's chorea. Biol Psychiatry (1988) 0.85
Time course of choice reaction time deficits in the Hdh(Q92) knock-in mouse model of Huntington's disease in the operant serial implicit learning task (SILT). Behav Brain Res (2008) 0.79
Characterization of the anxiolytic-like effects of fluvoxamine, milnacipran and risperidone in mice using the conditioned fear stress paradigm. Eur J Pharmacol (2004) 0.78
Effects of Ca2+ antagonists on motor activity and the dopaminergic system in aged mice. Neurobiol Aging (2002) 0.77
A conserved DNA sequence in homoeotic genes of the Drosophila Antennapedia and bithorax complexes. Nature (1984) 6.62
Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control (2001) 5.38
Sedimentation of generalized systems of interacting particles. I. Solution of systems of complete Lamm equations. Biopolymers (1975) 4.49
Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet (2007) 4.45
In vivo splicing products of the rabbit beta-globin pre-mRNA. Cell (1984) 3.35
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res (1994) 3.30
Hospital peer review and the National Practitioner Data Bank: clinical privileges action reports. JAMA (1999) 3.24
Specificity of salivary-bacterial interactions: role of terminal sialic acid residues in the interaction of salivary glycoproteins with Streptococcus sanguis and Streptococcus mutans. Infect Immun (1978) 3.12
Synergistic activation and repression of transcription by Drosophila homeobox proteins. Cell (1989) 3.01
Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet (2000) 2.95
Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta (1993) 2.92
Social network ties and mortality among the elderly in the Alameda County Study. Am J Epidemiol (1987) 2.69
A new surgical procedure for the treatment of gastroesophageal reflux and hiatal hernia. Surg Gynecol Obstet (1979) 2.57
Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol (2009) 2.52
RNA-mediated gene duplication: the rat preproinsulin I gene is a functional retroposon. Mol Cell Biol (1985) 2.35
Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med (1990) 2.33
The ethics objective structured clinical examination. J Gen Intern Med (1993) 2.32
Are neostriatal dopamine receptors co-localized? Trends Neurosci (1993) 2.28
Fungal flora of the normal human small and large intestine. N Engl J Med (1969) 2.25
Pre-mRNA splicing and the nuclear matrix. Mol Cell Biol (1987) 2.22
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol (2000) 2.13
Plain film diagnosis of the acute abdomen. Emerg Med Clin North Am (1985) 2.11
Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc Natl Acad Sci U S A (1993) 2.08
CaMKIIalpha-Cre transgene expression and recombination patterns in the mouse brain. Genesis (2000) 2.04
Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology (2008) 2.04
Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum. Dev Neurosci (1998) 2.01
Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. Clin Endocrinol (Oxf) (1998) 1.99
Effect of a tumour promoter on myogenesis. Nature (1977) 1.98
Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest (2000) 1.94
Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J Neurophysiol (2001) 1.91
Graduates of foreign medical schools: demographic and personal predictors of success on an OSCE-format internship programme entrance examination. Res Med Educ (1988) 1.86
Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res (2001) 1.79
Congenital esophageal stenosis in adults. Am J Gastroenterol (2000) 1.77
NMDA receptor function in mouse models of Huntington disease. J Neurosci Res (2001) 1.76
Reliability and construct validity of a structured technical skills assessment form. Am J Surg (1994) 1.72
Rat insulin-like growth factor II gene. A single gene with two promoters expressing a multitranscript family. J Mol Biol (1986) 1.72
Conditional mutagenesis in mice with heat shock promoter-driven cre transgenes. Mamm Genome (2000) 1.71
Identification of a regulatory region that mediates glucose-dependent induction of the Saccharomyces cerevisiae enolase gene ENO2. Mol Cell Biol (1986) 1.69
Portal venous gas as a complication of ERCP and endoscopic sphincterotomy. Am J Gastroenterol (1995) 1.65
Sedimentation of generalized systems of interacting particles. II. Active enzyme centrifugation--theory and extensions of its validity range. Biopolymers (1975) 1.64
Shared decision making for in-patients with schizophrenia. Acta Psychiatr Scand (2006) 1.63
Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. Neuroscience (2011) 1.62
Airborne endotoxin associated with industrial-scale production of protein products in gram-negative bacteria. Am Ind Hyg Assoc J (1988) 1.61
Paclitaxel-based chemotherapy in carcinoma of the fallopian tube. Gynecol Oncol (2001) 1.59
Resistance to macrolides in Streptococcus pyogenes in France in pediatric patients. Antimicrob Agents Chemother (2000) 1.57
Benefits of Ophdiat, a telemedical network to screen for diabetic retinopathy: a retrospective study in five reference hospital centres. Diabetes Metab (2009) 1.56
Laparascopic excision of pelvic kidney with single vaginal ectopic ureter. J Pediatr Surg (1997) 1.56
Percolation in directed scale-free networks. Phys Rev E Stat Nonlin Soft Matter Phys (2002) 1.56
Killian-Jamieson diverticula: radiographic findings in 16 patients. AJR Am J Roentgenol (2001) 1.56
Structural family versus psychodynamic child therapy for problematic Hispanic boys. J Consult Clin Psychol (1989) 1.53
Inhaled antibiotics in cystic fibrosis. Lancet (1983) 1.53
Comparison of the 15q deletions in Prader-Willi and Angelman syndromes: specific regions, extent of deletions, parental origin, and clinical consequences. Am J Med Genet (1990) 1.53
Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J Neurosci (2001) 1.52
Is the period of rapidly declining adult mortality in the United States coming to an end? Am J Public Health (1983) 1.50
The type 2 family: a setting for development and treatment of adolescent type 2 diabetes mellitus. Arch Pediatr Adolesc Med (1999) 1.49
Minimal exon sequence requirements for efficient in vitro splicing of mono-intronic nuclear pre-mRNA. J Biol Chem (1987) 1.48
Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J Neurosci Res (1999) 1.48
Ventricular laceration and cardiac tamponade during laparoscopic Nissen fundoplication. Surg Laparosc Endosc (1996) 1.48
Gastric bezoars: reassessment of clinical and radiographic findings in 19 patients. Br J Radiol (2009) 1.48
Crohn's disease arthritis treated with infliximab: an open trial in four patients. J Clin Rheumatol (2001) 1.46
Dopaminergic modulation of NMDA-induced whole cell currents in neostriatal neurons in slices: contribution of calcium conductances. J Neurophysiol (1998) 1.46
Guidelines for estimating the real cost of an objective structured clinical examination. Acad Med (1993) 1.45
Vaccination against meningococcus C. vaccinal coverage in the French target population. Med Mal Infect (2013) 1.45
Increasing trends in the use of breast-conserving surgery in California. Am J Public Health (2000) 1.44
Normal viral and bacterial flora of the human small and large intestine. N Engl J Med (1966) 1.44
Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children. Clin Infect Dis (2014) 1.44
Congenital esophageal stenosis in a 21-year-old man: clinical and radiographic findings. AJR Am J Roentgenol (1998) 1.42
Sexual agglutinins from the Chlamydomonas flagellar membrane. Partial purification and characterization. J Biol Chem (1982) 1.42
Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol (1999) 1.41
An objective structured clinical examination for the licentiate of the Medical Council of Canada: from research to reality. Acad Med (1993) 1.41
Undifferentiated (embryonal) sarcoma of the liver: pathologic basis of imaging findings in 28 cases. Radiology (1997) 1.40
Visualization of areae gastricae on double-contrast upper gastrointestinal radiography: relationship to age of patients. AJR Am J Roentgenol (2001) 1.39
[Meningeal myelomatosis. Presentation of a case]. Sangre (Barc) (1992) 1.38
Analysis of excess lung cancer risk in short-term employees. Am J Epidemiol (1988) 1.38
The hot clot sign. A new finding in deep venous thrombosis on bone scintigraphy. Clin Nucl Med (1990) 1.38
[Treatment of Streptococcus pneumoiae meningitis in infants]. Arch Pediatr (1994) 1.37
In vitro killing activities of antibiotics at clinically achievable concentrations in cerebrospinal fluid against penicillin-resistant Streptococcus pneumoniae isolated from children with meningitis. Antimicrob Agents Chemother (1994) 1.37
Factors contributing to physicians' success in the advanced trauma life support program in Israel. Isr Med Assoc J (1999) 1.36
Null mutation of the murine ATP7B (Wilson disease) gene results in intracellular copper accumulation and late-onset hepatic nodular transformation. Hum Mol Genet (1999) 1.36
Mouse mutant embryos lacking huntingtin are rescued from lethality by wild-type extraembryonic tissues. Development (1998) 1.35
A comparative analysis of the costs of administration of an OSCE (objective structured clinical examination). Acad Med (1994) 1.34
Combined ileal heterotopic pancreatic and gastric tissues causing ileocolic intussusception in an infant. Pediatr Surg Int (2005) 1.33
Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing. Neurobiol Dis (2005) 1.33
Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein. Neuroscience (2006) 1.32
Microbial intestinal flora in acute diarrheal disease. JAMA (1967) 1.30
The screw gene encodes a ubiquitously expressed member of the TGF-beta family required for specification of dorsal cell fates in the Drosophila embryo. Genes Dev (1994) 1.28
Impact of antimicrobial therapy on nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, and Branhamella catarrhalis in children with respiratory tract infections. Clin Infect Dis (2000) 1.27
Meckel's enteroliths: clinical, radiologic, and pathologic findings. AJR Am J Roentgenol (1996) 1.27
Ventilatory and diffusion abnormalities in potential heart transplant recipients. Chest (1990) 1.25
Guinea pig preproinsulin gene: an evolutionary compromise? Proc Natl Acad Sci U S A (1984) 1.24
Cryoglobulins. III. Further studies on the nature, incidence, clinical, diagnostic, prognostic, and immunopathologic significance of cryoproteins in renal disease. Q J Med (1975) 1.24
Functional analysis of mononuclear cells infiltrating into tumors: lysis of autologous human tumor cells by cultured infiltrating lymphocytes. Cancer Res (1987) 1.23
Murine Hox-1.7 homeo-box gene: cloning, chromosomal location, and expression. Mol Cell Biol (1987) 1.23
Metformin and digestive disorders. Diabetes Metab (2011) 1.22
Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor-deficient mice. J Neurophysiol (2001) 1.21
Changes in apparent body orientation and sensory localization induced by vibration of postural muscles: vibratory myesthetic illusions. Aviat Space Environ Med (1979) 1.20
Pregnancy and idiopathic autoimmune haemolytic anaemia: a prospective study during 6 months gestation and 3 months post-partum. Br J Haematol (1973) 1.19